biosimilar

A generic copy of a small-molecule pill is straightforward because the molecule is small and can be reproduced atom for atom. A biologic drug — an antibody or therapeutic protein — is a huge, intricate molecule grown inside living cells, and no two manufacturers can make it perfectly identically. A biosimilar is the closest equivalent the law allows: a follow-on biologic that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety or effectiveness.

Because the product cannot be proven chemically identical, approval rests on demonstrating similarity rather than sameness. Developers run extensive analytical characterization to show the molecule's structure, purity, and biological activity match the reference closely, supported by comparative functional, pharmacokinetic, and usually clinical studies. This is a far larger task than a small-molecule generic but far smaller than developing a brand-new biologic from scratch, which is the point: it brings competition and lower prices to expensive biologic medicines.

An important nuance is that biosimilar does not necessarily mean automatically substitutable at the pharmacy. Reference biologics themselves drift slightly batch to batch, so similar-but-not-identical is the realistic standard even for the original. Regulators judge a biosimilar acceptable when the residual differences are shown to be clinically irrelevant — a meaningfully higher bar than the chemical identity expected of a generic.